High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase cronich myeloid leukemia: first result from the randomized CELSG phrase III CML 11 "ISTAHIT"study

Petzer, A., Goranov, S., & al., e. (2010). High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase cronich myeloid leukemia: first result from the randomized CELSG phrase III CML 11 "ISTAHIT"study. Haematologica. Pavia: 95 (6), 908-913.